Exenatide treatment alleviated symptoms of depression in patients

August 1, 2018, IOS Press

Non-motor symptoms of Parkinson's disease (PD), such as depression, apathy, cognitive impairment, sleep disorders, and sensory symptoms, can have a greater impact on health-related quality of life than motor deficits. In a post hoc analysis of the exenatide-PD trial results, investigators found that patients on exenatide treatment experienced improvements in severity of depression, independent of whether their motor function improved. They report their findings in the Journal of Parkinson's Disease.

GLP-1 receptor agonists are used to treat people with type 2 diabetes by stimulating the GLP-1 receptors in the pancreas, which triggers the release of insulin. GLP-1 receptors have been found in the brain and may also play a role to in the treatment of PD. In the -PD trial, a randomized, placebo-controlled clinical trial in patients with moderate-stage PD, the GLP-1 receptor agonist exenatide showed positive effects on the motor severity of the disease, which continued 12 weeks beyond the period of exenatide exposure.

"In the original analysis of the exenatide-PD trial, the primary outcome was a comparison in the motor severity of PD," explained Thomas Foltynie, Ph.D., MBBS, Sobell Department of Motor Neuroscience, UCL Institute of Neurology, and The National Hospital for Neurology and Neurosurgery, London, UK, who led the exenatide trial and is lead investigator of the current study. "Analysis of pre-defined secondary outcomes revealed no statistically significant differences between patients treated with exenatide in total non-motor burden and overall quality of life measures, including the Non Motor Symptoms Scale (NMSS). However, the response of individual non-motor symptoms to an intervention may vary."

The current research was a of the trial data and aimed to identify whether in addition to improvement in motor function, there were any indications that exenatide affected specific non-motor symptoms of PD compared to placebo, rather than considering the non-motor symptoms severity scale as a whole.

Results indicated that all measures evaluating depression improved in patients who received exenatide. The proportion of patients reporting depressive symptoms in the placebo group increased from 17% at baseline to 25% at 48 weeks, while in the exenatide group, the proportion of patients reporting depressive symptoms reduced from 23% at baseline to 6% of patients at 48 weeks. Among the other post hoc comparisons of specific non-motor symptoms, self-reported apathy and cognition also improved with exenatide.

These results are of particular interest given the effects on mood appear to be independent from the previously reported beneficial effects on . Furthermore, they are consistent with laboratory data indicating that exenatide has potential beneficial effects on mood in animal models.

"These data should be considered as hypothesis-generating rather than formal evidence to support an effect of exenatide on mood or cognition and should not be used to influence patient treatment decisions. Nevertheless, we will consider carefully how best to capture mood severity in planned future trials of exenatide in PD," commented Professor Foltynie.

"The study of potential benefits of anti-diabetic agents that might modify disease progression in Parkinson's is a vibrant research area. Not only are we learning about what the effects of the drugs might be in , but emerging parallel work in laboratories is also beginning to unravel the underlying mechanisms of action of the drugs in the brain," added Patrik Brundin, MD, Ph.D., Associate Director of Research, Professor and Director of the Center for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, MI, and Co-Editor-in-Chief of the Journal of Parkinson's Disease.

Explore further: Diabetes drug tested in Parkinson's disease patients

More information: Dilan Athauda et al, What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: A Post Hoc Analysis, Journal of Parkinson's Disease (2018). DOI: 10.3233/JPD-181329

Related Stories

Diabetes drug tested in Parkinson's disease patients

May 20, 2013
Parkinson's disease (PD) is a degenerative neurological disorder marked by a progressive loss of motor control. Despite intensive research, there are currently no approved therapies that have been demonstrated to alter the ...

Diabetes drug shows potential as disease-modifying therapy for Parkinson's disease

August 3, 2017
A drug commonly used to treat diabetes may have disease-modifying potential to treat Parkinson's disease, a new UCL-led study suggests, paving the way for further research to define its efficacy and safety.

Exenatide has potential as a disease modifying agent in Parkinson's disease

May 6, 2014
A follow-up study of patients with Parkinson's disease (PD) who participated in an earlier "proof of concept" clinical trial using exenatide showed that improvements persisted twelve months after discontinuing exenatide therapy. ...

Exenatide twice daily deemed efficacious across BMI ranges

April 11, 2016
(HealthDay)—For patients with type 2 diabetes, exenatide twice daily added to insulin glargine is efficacious across body mass index (BMI) ranges, according to a study published online March 29 in Diabetes, Obesity and ...

Exenatide does not promote weight loss in schizophrenia

October 5, 2016
(HealthDay)—For antipsychotic-treated obese patients with schizophrenia, glucagon-like peptide-1 receptor agonists (GLP-1RAs) do not appear to promote weight loss, according to a study published online Sept. 26 in Diabetes, ...

Exenatide doesn't up cardiovascular risk in T2DM

September 15, 2017
(HealthDay)—For patients with type 2 diabetes, the incidence of major cardiovascular events is similar for those receiving exenatide or placebo, according to a study published online Sept. 14 in the New England Journal ...

Recommended for you

First-of-its-kind Parkinson's biomarker guidelines invigorates drive for treatments

August 15, 2018
Parkinson's disease affects more than 4 million people worldwide, with numbers projected to double in the next few decades. With no known cure, there is a race for treatments to slow or stop the progression of the disease. ...

Study identifies chaperone protein implicated in Parkinson's disease

August 13, 2018
Reduced levels of a chaperone protein might have implications for the development and progression of neurodegenerative diseases such as Parkinson's disease and Lewy body dementia, according to new research from investigators ...

Function of gene mutations linked to neurological diseases identified

August 10, 2018
Several gene mutations have been linked to Parkinson's disease, but exactly how and where some of them cause their damage has been unclear. A new Yale study, published in the Journal of Cell Biology, shows that one of the ...

Biomarkers link fatigue in cancer, Parkinson's

August 9, 2018
Biological markers responsible for extreme exhaustion in patients with cancer have now been linked to fatigue in those with Parkinson's disease, according to new research from Rice University.

Researchers examining Parkinson's resilience

August 2, 2018
Diseases have a spectrum of risk, even those partially embedded in genes such as Parkinson's disease.

Japan human trial tests iPS cell treatment for Parkinson's

July 30, 2018
Japanese researchers on Monday announced the first human trial using a kind of stem cell to treat Parkinson's disease, building on earlier animal trials.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Anonym326885
not rated yet Aug 08, 2018
The love of my life for the last 17 years was diagnosed with Parkinson's disease nearly 4 years ago, at age 52. He had a stooped posture, tremors, muscle stiffness, horrible driving skills, and slow movement. He was placed on Sinemet 50/200 at night for 7 months and then Sifrol and rotigotine were introduced which replaced the Sinemet but he had to stop due to side effects. He started having hallucinations, lost touch with reality. Suspecting it was the medications I took him off the Siferol (with the doctor's knowledge) In March this year his primary physician suggested we started him on Natural Herbal Gardens Parkinson's Herbal formula which eased his anxiety a bit, i'm happy to report this PD herbal treatment worked very effectively. His Parkinson's is totally under control, he had a total decline in symptoms, the tremors, shaking, stiffness, slow movement and speech problems stopped. Visit Natural Herbal Gardens official web page ww w. naturalherbalgardens. c om.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.